Biological products and methods of use and applications thereof

Through the exogenous supplementation of recombinant butyrylcholinesterase-albumin fusion protein and recombinant butyrylcholinesterase-Fc fusion protein, the problem of decreased expression of cholinesterase in cancer was solved, and the to-many was achieved The treatment effect of cancer and overcomes the cost and safety risks of traditional methods.

CN118542931BActive Publication Date: 2024-11-15SHANGHAI JENOMED BIOTECH CO LTD
View PDF 12 Cites 0 Cited by

Patent Information

Application Number
CN202411025590.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-07-30
Publication Date
2024-11-15
Estimated Expiration
2044-07-30

AI Technical Summary

Technical Problem

The prior art is difficult to effectively solve the problem of decreased expression or activity of cholinesterase in cancer, and isolation and purification of cholinesterase from human plasma is expensive and has a risk of spreading infectious pathogens.

Method used

Provides a biological product, including recombinant butyrylcholinesterase-albumin fusion protein and recombinant butyrylcholinesterase-Fc fusion protein, to adjust the balance of acetylcholine by exogenous supplementation of cholinesterase for treatment Various cancers. The biological product is produced through the animal breast bioreactor pharmaceutical platform, using animal expression systems such as CHO cells or insect expression systems, combining flexible linking peptides and purified tag sequences, and is absorbed into the human body through transdermal absorption.

Benefits of technology

The balance of adjusting acetylcholine and related metabolic pathways in vivo was achieved, significantly prolonging the half-life of biological products, improving the therapeutic effect on a variety of cancers, and overcoming the cost and safety risks of traditional methods.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118542931B_ABST
    Figure CN118542931B_ABST
Patent Text Reader

Abstract

This invention provides a biological product, its method of use, and its application. The biological product is used to prepare a drug for treating tumors. The biological product comprises at least one of recombinant butyrylcholinesterase-albumin fusion protein and recombinant butyrylcholinesterase-Fc fusion protein. The biological product achieves the therapeutic effect of cancer by supplementing exogenous at least one of the recombinant butyrylcholinesterase-albumin fusion protein and recombinant butyrylcholinesterase-Fc fusion protein to adjust the balance of acetylcholine and other related metabolic pathways. This invention solves the problem that the extraction and purification of cholinesterase from human plasma may not meet the huge demand for cancer treatment. This invention also provides the application of the biological product in neutralizing and degrading nerve agents and organophosphate poisons, hydrolyzing starvation hormones, and in anti-wrinkle applications.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to a biological product and a method for using and applying the same. Background Art

[0002] Cholinesterases are divided into two major categories. Those that preferentially hydrolyze acetylcholine esters such as acetylcholine, whose enzymatic activity is sensitive to the chemical inhibitor BW284C51, are called acetylcholinesterase (AChE), or acetylcholine acetylhydrolase. Acetylcholinesterase, also known as true, specific, pure, erythrocytic or type I cholinesterase, is a membrane-bound glycoprotein and is present in different molecular forms in red blood cells, nerve endings, lungs, spleen and gray matter of the brain. Acetylcholinesterase is mainly used to hydrolyze acetylcholine in the body. Those enzymes that preferentially hydrolyze other esters such as butyrylcholine, whose enzymatic activity is sensitive to the chemical inhibitor tetraisopropyl pyrophosphamide (ISO-OMPA), are called butyrylcholinesterase (BChE, EC 3.1.1.8).

[0003] Butyrylcholinesterase is also known as pseudobutyrylcholinesterase or nonspecific butyrylcholinesterase. Butyrylcholinesterase is further classified according to its charge, hydrophobicity, interaction with cell membranes or extracellular structures, and subunit composition. The enzyme is also known as plasma, serotype, benzoyl, pseudo or type II cholinesterase, and there are more than 11 isozyme variants. Butyrylcholinesterase preferentially uses butyrylcholine and benzoylcholine as its in vitro reaction substrates. The enzyme is present in mammalian plasma, liver, pancreas, intestinal mucosa, central nervous system white matter, smooth muscle and heart. Human plasma butyrylcholinesterase is a globular tetrameric serine esterase with a half-life of 12 days in human blood. It can neutralize and degrade nerve agents and other organophosphorus agents in the blood, preventing these agents from binding to acetylcholinesterase. At present, although butyrylcholinesterase can also hydrolyze acetylcholine, its other specific functions are still unclear because it has no known specific natural substrates.

[0004] In cancers related to the nervous system, respiratory tract, digestive tract, liver, and pancreas, there is a decrease in the expression or activity of cholinesterase; in tumors related to kidney, bladder, cervix, ovary, breast, prostate cancer, skin, soft tissue, and blood system, the enzyme activity or gene structure function of acetylcholinesterase or butyrylcholinesterase is defective; the lower the enzyme activity of acetylcholinesterase or butyrylcholinesterase in the tissues of patients with blood tumors, the worse the patient's prognosis. Recent studies have shown that in addition to the function of a neurotransmitter, acetylcholine is also an endogenous growth hormone. Overexpression or agonistic effects of acetylcholine receptors may induce the occurrence of cancer. This phenomenon is particularly significant in cancers caused by smoking, suggesting that excessive accumulation of acetylcholine or excessive agonistic effects of acetylcholine receptors may cause cancer. Some people have also suggested that the decrease in cholinesterase activity leads to the accumulation of acetylcholine in different tissues and organs, causing imbalance in the microenvironment, which may cause cancer. It is scientifically feasible to adjust the balance of acetylcholine to prevent and treat cancer by supplementing exogenous cholinesterase.

[0005] The cost of isolating and purifying cholinesterase directly from human plasma is high, and the concentration of cholinesterase in human plasma is extremely low. Therefore, the commercial value of isolating and purifying cholinesterase from human plasma is low, and there is also the risk of transmitting infectious pathogens including viruses such as hepatitis C and HIV.

[0006] Therefore, it is necessary to provide a biological product and a method and application thereof to avoid the above-mentioned problems existing in the prior art. Summary of the invention

[0007] The object of the present invention is to provide an application of a biological product, wherein the biological product is used to prepare a drug for treating tumors, and the biological product comprises at least one of a recombinant butyrylcholinesterase-albumin fusion protein and a recombinant butyrylcholinesterase-Fc fusion protein to adjust the balance of acetylcholine and other related metabolic pathways to achieve the purpose of treating cancer.

[0008] Optionally, the tumor includes liver cancer, small cell lung cancer, non-small cell lung cancer, pancreatic cancer, gastric cancer, esophageal cancer, breast cancer, ovarian cancer, cervical cancer, endometrial cancer, bladder cancer, colorectal cancer, prostate cancer, glioma, head and neck cancer or blood tumor.

[0009] Optionally, the amino acid sequence of the recombinant butyrylcholinesterase-albumin fusion protein is as shown in SEQ ID NO:1 or SEQ ID NO:2.

[0010] Optionally, the amino acid sequence of the recombinant butyrylcholinesterase-Fc fusion protein is as shown in SEQ ID NO:3 or SEQ ID NO:4.

[0011] Optionally, the recombinant butyrylcholinesterase-albumin fusion protein and the recombinant butyrylcholinesterase-Fc fusion protein are both from any one of an animal expression system, a viral transduction system, a plant expression system, a bacterial expression system, a CRISPR-Cas gene editing expression system and a yeast expression system.

[0012] Optionally, the insect expression system is an SF9 cell line.

[0013] Optionally, the mammalian expression system includes the following mammalian cell expression systems: CHO, BHK, bovine mammary epithelial cell MAC-T cell line, bovine mammary epithelial cell BME-UV1 cell line, and HEK293.

[0014] Optionally, the animal expression system includes any one or more of the mammary gland bioreactor systems of mice, rats, rabbits, goats, sheep, pigs, camels, yaks, buffaloes and cows.

[0015] Optionally, the recombinant butyrylcholinesterase-albumin fusion protein and the recombinant butyrylcholinesterase-Fc fusion protein further include a flexible connecting peptide between the two proteins, for example, any one of a Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser-Gly-Gly connecting peptide, a Gly-Gly-Gly-Gly-Gly-Ser connecting peptide, and a Gly-Gly-Gly-Gly-Gly-Gly-Gly-Ser connecting peptide.

[0016] Optionally, the N-terminus or C-terminus of the recombinant butyrylcholinesterase-albumin fusion protein and the recombinant butyrylcholinesterase-Fc fusion protein also includes a tag sequence for facilitating protein purification, and the tag sequence is any one or more of His, Flag, MBP, GST, HA and Myc.

[0017] Optionally, the biological product is introduced into the human body through transdermal absorption, including simultaneous transdermal absorption of TD-1 or other transdermal short peptides.

[0018] Optionally, the present invention also provides a use of a biological product in neutralizing and degrading nerve agents and organophosphorus agents, hydrolyzing hunger hormones and anti-wrinkle. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 This is a graph showing the relationship between the relative enzyme activity and absorbance of a diluted sample of the rabbit milk recombinant butyrylcholinesterase of Example 1 of the present invention measured by Ellman assay;

[0020] Figure 2This is a photograph of the electrophoresis diagram of the recombinant butyrylcholinesterase produced in rabbit milk after purification by SDS-PAGE electrophoresis and Coomassie brilliant blue staining in Example 1 of the present invention;

[0021] Figure 3 The electrophoretic picture of the diluted mouse milk sample containing the recombinant butyrylcholinesterase-albumin fusion protein and the recombinant butyrylcholinesterase-Fc fusion protein of Example 2 of the present invention displayed by denaturing SDS-PAGE electrophoresis and silver staining;

[0022] Figure 4 This is a schematic diagram of the experimental results of the growth inhibition of different tumor cell lines by the recombinant butyrylcholinesterase produced by rabbit milk according to Example 3 of the present invention;

[0023] Figure 5 This is a photograph of the SDS-PAGE electrophoresis of the recombinant butyrylcholinesterase-Fc fusion protein of Example 4 of the present invention after expression and purification in CHO cells;

[0024] Figure 6 The electrophoretic images of human serum butyrylcholinesterase, recombinant butyrylcholinesterase produced by rabbit milk and recombinant butyrylcholinesterase-Fc fusion protein produced by CHO cells shown by non-denaturing gel electrophoresis in Example 4 of the present invention;

[0025] Figure 7 This is a schematic diagram of the duration of human butyrylcholinesterase activity in the plasma of experimental mice in Example 4 of the present invention after intravenous or intraperitoneal injection of human serum butyrylcholinesterase, recombinant butyrylcholinesterase produced by rabbit milk, and recombinant butyrylcholinesterase-Fc fusion protein produced by CHO cells;

[0026] Figure 8 This is a schematic diagram of the experimental results of the growth inhibition of different tumor cell lines by the recombinant butyrylcholinesterase-Fc fusion protein produced by CHO cells in Example 5 of the present invention. DETAILED DESCRIPTION

[0027] In order to make the purpose, technical solution and advantages of the present invention clearer, the technical solution in the embodiment of the present invention will be clearly and completely described below in conjunction with the drawings of the present invention. Obviously, the described embodiment is a part of the embodiment of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention. Unless otherwise defined, the technical terms or scientific terms used herein should be understood by people with general skills in the field to which the present invention belongs. "Include" and "comprising" and similar words used in this article mean that the elements or objects appearing before the word cover the elements or objects listed after the word and their equivalents, without excluding other elements or objects.

[0028] In order to mass produce recombinant butyrylcholinesterase for medicinal use, the present invention has established an animal mammary bioreactor pharmaceutical platform, produced several recombinant butyrylcholinesterase-positive rabbit lines, screened several rabbit milk-produced recombinant butyrylcholinesterase high-expression lines, and purified a portion of the protein. The results of the present invention show that the enzyme kinetic parameters of the recombinant butyrylcholinesterase produced in rabbit milk are the same as those of human serum butyrylcholinesterase.

[0029] In order to overcome the short half-life of recombinant butyrylcholinesterase produced in rabbit milk, the present invention expresses and purifies milligram-level recombinant butyrylcholinesterase-Fc fusion protein in CHO cells by transient transfection. The experimental results show that the enzymatic kinetic parameters, enzyme activity and in vivo pharmacokinetic parameters of the fusion protein are basically the same as those of human serum butyrylcholinesterase.

[0030] In view of the problems existing in the prior art, an embodiment of the present invention provides an application of a biological product, which is used to prepare a drug for treating tumors. The biological product includes at least one of a recombinant butyrylcholinesterase-albumin fusion protein and a recombinant butyrylcholinesterase-Fc fusion protein. The biological product adjusts the balance of acetylcholine and other related metabolic pathways by supplementing at least one of the exogenous recombinant butyrylcholinesterase-albumin fusion protein and the recombinant butyrylcholinesterase-Fc fusion protein to achieve the purpose of treating cancer.

[0031] In some embodiments of the present invention, the tumor includes but is not limited to liver cancer, small cell lung cancer, non-small cell lung cancer, pancreatic cancer, gastric cancer, esophageal cancer, breast cancer, ovarian cancer, cervical cancer, endometrial cancer, bladder cancer, colorectal cancer, prostate cancer, brain glioma, head and neck cancer or blood tumor.

[0032] In some embodiments of the present invention, the recombinant butyrylcholinesterase-albumin fusion protein can not only exert the biological activity of the fusion protein, but also human serum albumin is the most abundant protein in the blood, maintaining the body's nutrition and osmotic pressure. Its half-life is as long as 15-19 days, and it also has the function of transporting drugs, which can significantly prolong the half-life of the fusion protein.

[0033] In some embodiments of the present invention, the recombinant butyrylcholinesterase-Fc fusion protein can not only exert the biological activity of the fusion protein, but also has some properties of antibodies, such as causing antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity and antibody-dependent cell-mediated phagocytosis.

[0034] In some embodiments of the present invention, the recombinant butyrylcholinesterase-albumin fusion protein and the recombinant butyrylcholinesterase-Fc fusion protein are both derived from any one of an animal expression system, a viral transduction system, a plant expression system, a bacterial expression system, a CRISPR-Cas gene editing expression system and a yeast expression system.

[0035] In some embodiments of the present invention, the animal expression system is selected from any one of an insect expression system and a mammalian expression system.

[0036] In some further specific embodiments of the present invention, the mammalian expression system comprises a mammalian cell expression system.

[0037] In some embodiments of the present invention, the animal expression system comprises any one or more of the mammary gland bioreactor systems of mice, rats, rabbits, goats, sheep, pigs, camels, yaks, buffaloes and cows.

[0038] Specifically, the animal mammary bioreactor system refers to constructing an expression vector using the regulatory sequence of a milk protein gene specifically expressed in the mammary gland, introducing the expression vector into the gene of a female non-human mammal of childbearing age and localizing the expression of the recombinant protein in the mammary tissue or mammary duct of the female non-human mammal of childbearing age; or transfecting the expression vector into the mammary tissue or mammary duct of the female non-human mammal of childbearing age; guiding the specific exogenous gene to be expressed specifically and efficiently in the animal mammary gland, in order to obtain exogenous active protein from the secreted milk.

[0039] In some possible embodiments of the present invention, the mammalian mammary gland expression system and the plant expression system are not obtained through genetic engineering.

[0040] In some specific embodiments of the present invention, the recombinant butyrylcholinesterase-albumin fusion protein and the recombinant butyrylcholinesterase-Fc fusion protein are derived from animal milk.

[0041] In some more specific embodiments of the present invention, the animal milk includes any one or more of milk from mice, rats, rabbits, goats, sheep, pigs, camels, yaks, buffaloes and cows.

[0042] In some more specific embodiments of the present invention, the insect cell expression system is the SF9 cell line.

[0043] In some more specific embodiments of the present invention, the mammalian cell expression system is a Chinese hamster ovary cell line (CHO), including but not limited to CHO-K1, CHO-DG44 and CHO-S.

[0044] In some more specific embodiments of the present invention, the mammalian cell expression system is a baby hamster kidney cell line (BHK).

[0045] In some more specific embodiments of the present invention, the mammalian cell expression system is a bovine mammary epithelial cell MAC-T cell line, a bovine mammary epithelial cell BME-UV1 cell line, and other primary mammary epithelial cells and mammary epithelial cell lines of cows, sheep and rabbits.

[0046] In some more specific embodiments of the present invention, the human cell expression system is a HEK293 cell line.

[0047] In some embodiments of the present invention, the amino acid sequence of the recombinant butyrylcholinesterase-albumin fusion protein is shown as SEQ ID NO:1 or SEQ ID NO:2, and the amino acid sequence of the recombinant butyrylcholinesterase-Fc fusion protein is shown as SEQ ID NO:3 or SEQ ID NO:4.

[0048] It should be understood that the amino acid sequences in the recombinant butyrylcholinesterase-albumin fusion protein are arranged in order; the specific arrangement order is the fusion of recombinant butyrylcholinesterase and albumin with an amino acid sequence such as SEQ ID NO: 1, and the fusion of albumin and recombinant butyrylcholinesterase with an amino acid sequence such as SEQ ID NO: 2.

[0049] Of course, the amino acid sequence in the recombinant butyrylcholinesterase-albumin fusion protein is not limited to being arranged in sequence. For example, for experimental needs, the amino acid sequence of albumin can be inserted into the amino acid sequence of recombinant butyrylcholinesterase. This is not limited to the above examples and will not be repeated here.

[0050] It should be understood that the amino acid sequences in the recombinant butyrylcholinesterase-Fc fusion protein are arranged in order; the specific order of arrangement is the fusion of the recombinant butyrylcholinesterase and Fc of the amino acid sequence such as SEQ ID NO: 3, and the fusion of the Fc fragment and the recombinant butyrylcholinesterase of the amino acid sequence such as SEQ ID NO: 4.

[0051] It should be noted that the amino acid sequence in the recombinant butyrylcholinesterase-Fc complex protein is not limited to being arranged in sequence. For example, in order to meet the needs of the experimental scenario, the amino acid sequence of Fc can be inserted into the amino acid sequence of the recombinant butyrylcholinesterase. This is not limited to the above examples and will not be repeated here.

[0052] In some embodiments of the present invention, the recombinant butyrylcholinesterase-albumin fusion protein and the recombinant butyrylcholinesterase-Fc fusion protein further include a flexible connecting peptide between the two proteins, and the flexible connecting peptide is any one of a Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser connecting peptide and a Gly-Gly-Gly-Gly-Gly-Gly-Ser connecting peptide, but is not limited to a Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser-Gly-Gly connecting peptide, a Gly-Gly-Gly-Gly-Gly-Ser connecting peptide and a Gly-Gly-Gly-Gly-Gly-Gly-Ser connecting peptide.

[0053] It should be understood that in the two application environments of the recombinant butyrylcholinesterase-albumin fusion protein, a flexible connecting peptide is added between the two proteins. In the two application environments of the recombinant butyrylcholinesterase-Fc fusion protein, a flexible connecting peptide is added between the two proteins.

[0054] In some embodiments of the present invention, the N-terminus or C-terminus of the recombinant butyrylcholinesterase-albumin fusion protein and the recombinant butyrylcholinesterase-Fc fusion protein also includes a tag sequence for facilitating protein purification, and the tag sequence is any one or more of His, Flag, MBP, GST, HA and Myc.

[0055] In some specific embodiments of the present invention, the biological product is introduced into the human body through transdermal absorption, including simultaneous transdermal absorption of TD-1 or other transdermal short peptides.

[0056] In some specific embodiments of the present invention, the TD-1 consists of 11 amino acids (Ala-Cys-Ser-Ser-Ser-Pro-Ser-Lys-His-Cys-Gly) and is the first transdermal enhancement peptide discovered by phage display technology.

[0057] In some specific embodiments of the present invention, the other transdermal short peptides also include a membrane-penetrating polypeptide composed of 22 amino acids (Cys-His-His-His-His-His-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Arg-His-His-His-His-His-Cys).

[0058] In some embodiments of the present invention, the transdermal short peptide is prepared by artificial synthesis.

[0059] In some embodiments of the present invention, the purity of the recombinant butyrylcholinesterase-albumin fusion protein, the recombinant butyrylcholinesterase-Fc fusion protein and the transdermal short peptide are all above 95%.

[0060] In some embodiments of the present invention, the repeated use time includes use every day, use every other day, or use at intervals of about 1 week to 26 weeks to enhance its application effect.

[0061] In some embodiments of the present invention, there is also provided a use of a biological product in neutralizing and degrading nerve agents and organophosphorus agents, hydrolyzing hunger hormones and anti-wrinkle.

[0062] Example 1 High-efficiency expression of recombinant butyrylcholinesterase produced in rabbit milk

[0063] The recombinant butyrylcholinesterase (amino acid sequence as shown in SEQ ID NO: 5) protein encoding nucleic acid plasmid was introduced into the gene of female rabbits of reproductive age, and the recombinant butyrylcholinesterase was expressed in the mammary tissue of the female rabbits of reproductive age, and rabbit milk was collected. The expression concentration of recombinant butyrylcholinesterase in rabbit milk was detected by Ellman assay. In several positive rabbit lines, high-efficiency expression of recombinant butyrylcholinesterase in rabbit milk was achieved (0.24-12 g / L, such as Figure 1 As shown in Table 1-1), the concentration of human serum butyrylcholinesterase separated and purified from human plasma is more than 6000 times higher, breaking through the technical bottleneck of mass production and achieving unexpected optimal technical results. The rabbit milk primary pure product containing recombinant butyrylcholinesterase was purified by affinity chromatography and ion exchange chromatography. The washed rabbit milk primary pure product was loaded onto a procainamide affinity chromatography column, which was pre-equilibrated with 10 mM phosphate buffer (pH 7.2), 1 mM EDTA and 140 mM NaCl. The column was washed with 10 bed volumes of the same equilibration buffer, and the protein was eluted with 10 mM phosphate buffer (pH 7.2), 1 mM EDTA and 500 mM NaCl. The eluate was loaded onto an HQ50 ion exchange chromatography column, which was equilibrated with the same buffer. The eluate was collected and the column was subsequently washed with 10 mM phosphate buffer (pH 7.2), 1 mM EDTA, and 1 M NaCl to remove any trapped impurities. The purified recombinant butyrylcholinesterase was sterile filtered and stored at -20°C. The purified protein was tested for recombinant butyrylcholinesterase activity and the total protein concentration was determined.

[0064] Figure 11 is a graph showing the relationship between the relative enzyme activity and absorbance of the diluted sample of the rabbit milk recombinant butyrylcholinesterase in Example 1 of the present invention measured by the Ellman assay, and Table 1-1 is an experimental record of the enzyme activity converted into concentration of the diluted sample of the rabbit milk recombinant butyrylcholinesterase in Example 1 measured by the Ellman assay. Among them, the expression concentration of the D152 milk sample is 12 g / L. Figure 2 The electrophoretic picture of the recombinant butyrylcholinesterase after purification in Example 1 of the present invention is shown by SDS-PAGE electrophoresis and Coomassie brilliant blue staining. After the recombinant butyrylcholinesterase is purified, denaturing SDS-PAGE electrophoresis and Coomassie brilliant blue staining show that the molecular weight of the monomeric recombinant butyrylcholinesterase is about 95 kDa, the purity is greater than 95%, and the activity is greater than 700 U / mg.

[0065] Table 1-1 Experimental record of converting the enzyme activity of the diluted sample of rabbit milk recombinant butyrylcholinesterase in Example 1 into concentration measured by Ellman assay

[0066]

[0067] Example 2 High-efficiency expression of recombinant butyrylcholinesterase-albumin fusion protein and recombinant butyrylcholinesterase-Fc fusion protein in mouse milk

[0068] The protein encoding nucleic acid plasmids of the recombinant butyrylcholinesterase-albumin fusion protein (as shown in SEQ ID NO: 1) and the recombinant butyrylcholinesterase-Fc fusion protein (as shown in SEQ ID NO: 3) were respectively introduced into the genes of female mice of childbearing age, and the recombinant butyrylcholinesterase-albumin fusion protein and the recombinant butyrylcholinesterase-Fc fusion protein were expressed in the mammary tissue of the female mice of childbearing age, and mouse milk was collected. The expression concentrations of the recombinant butyrylcholinesterase-albumin fusion protein and the recombinant butyrylcholinesterase-Fc fusion protein in the mouse milk were respectively detected by the Ellman assay detection method.

[0069] Figure 3 The electrophoretic images of the diluted mouse milk samples containing the recombinant butyrylcholinesterase-albumin fusion protein and the recombinant butyrylcholinesterase-Fc fusion protein of Example 2 of the present invention are displayed by denaturing SDS-PAGE electrophoresis and silver staining. Among them, 1 shows the protein molecular weight marker; 2 shows the expression of about 95kDa recombinant butyrylcholinesterase in 1:1000 diluted rabbit milk; 3 shows the expression of about 130kDa recombinant butyrylcholinesterase-Fc fusion protein in 1:1000 diluted mouse milk; 4 shows the expression of about 170kDa recombinant butyrylcholinesterase-albumin fusion protein in 1:1000 diluted mouse milk. Using the Ellman assay detection method, the expression concentration of the diluted sample of recombinant butyrylcholinesterase expressed in rabbit milk was used as a control (by Figure 1It can be seen that the expression concentration of recombinant butyrylcholinesterase in rabbit milk is about 12 g / L). The expression concentrations of recombinant butyrylcholinesterase-albumin fusion protein and recombinant butyrylcholinesterase-Fc fusion protein in mouse milk were detected respectively. The expression concentrations of these recombinant fusion proteins in mouse milk are about 1-5 g / L.

[0070] Example 3 Growth inhibition experiment of recombinant butyrylcholinesterase produced by rabbit milk on different tumor cell lines

[0071] The liver cancer cell line Huh7 (derived from the JCRB cell bank), the colon cancer cell line SW48 (derived from the ECACC cell bank), the non-small cell lung cancer cell line NCI-H460 (derived from the ATCC cell bank) and the gastric cancer cell line Hs746T (derived from the ATCC cell bank) were seeded in a 96-well culture plate at 3000 cells per well and cultured overnight in Williams'Medium E (from Sigma-Aldrich) culture medium + 10% fetal bovine serum in a 5% CO2 incubator. The next day, the recombinant butyrylcholinesterase produced by rabbit milk purified in Example 1 was added to the wells at 0.5μM, 1.5μM and 2.5μM per well. After 72 hours of culture, 50ul Cell Titer Glo was added to each well of the culture plate to detect the proliferation of cells. The above experiment was repeated within one week. The specific experimental results are shown as follows. Figure 4 As shown in the figure, after treatment with 0.5 μM, 1.5 μM and 2.5 μM recombinant butyrylcholinesterase, the survival rates of the liver cancer cell line Huh7 were 75.5%, 47% and 18%, respectively. The half inhibitory concentration (IC 50 ) was 1.42 μm; the survival rates of colon cancer cell line SW48 were 76.5%, 54.4% and 29.6%, respectively. The half inhibitory concentration (IC 50 ) was 1.63 μm; the cell viability of the non-small cell lung cancer cell line NCI-H460 was 81%, 75.6% and 39.9% respectively. The half inhibitory concentration (IC 50 ) was 2 μm; the survival rates of gastric cancer cell line Hs746T cells were 72.3%, 66.7% and 48.5%, respectively. The half inhibitory concentration (IC 50 ) is 2.43μm; reference Figure 4 (Schematic diagram of the experimental results of the growth inhibition of different tumor cell lines by recombinant butyrylcholinesterase produced in rabbit milk). The experimental results show that the half-inhibitory concentration of recombinant butyrylcholinesterase produced in rabbit milk on the liver cancer cell line Huh7 is more than 10 times lower than the half-inhibitory concentration of liver cancer treatment drugs commonly used in clinical practice on Huh7; the half-inhibitory concentration of the enzyme on other tested cancer cell lines is also low, indicating that the recombinant butyrylcholinesterase product is a potential broad-spectrum cancer treatment drug.

[0072] Example 4 Expression and purification of recombinant butyrylcholinesterase-Fc fusion protein produced by CHO cells, in vitro activity and in vivo pharmacokinetic experiments in mice

[0073] The recombinant butyrylcholinesterase-Fc fusion protein (as shown in SEQ ID NO: 4) protein encoding nucleic acid plasmid was introduced into the CHO cell gene, and the long-acting recombinant butyrylcholinesterase was expressed and secreted to the cell surface, and the supernatant was collected and purified by column in one step.

[0074] The expression concentration of recombinant butyrylcholinesterase-Fc fusion protein in CHO cells is about 0.15 mg / ml, the purity after one-step column purification is 93%, and the molecular weight is about 250 KDa (dimer); Figure 5 . Figure 5 This is a photo of the SDS-PAGE electrophoresis of the recombinant butyrylcholinesterase-Fc fusion protein after expression and purification in CHO cells. Legend: R, reducing conditions; N, non-reducing conditions.

[0075] The Ellman assay was used to simultaneously detect the enzymatic kinetic parameters and protein activity of human serum butyrylcholinesterase, recombinant butyrylcholinesterase produced in rabbit milk, and recombinant butyrylcholinesterase-Fc fusion protein produced in CHO cells, see Table 4-1 and Table 4-2. The experimental results showed that the enzymatic kinetic parameters and enzyme activities of the three enzymes were roughly the same.

[0076] Table 4-1. Comparison of enzymatic kinetic parameters of three enzymes

[0077]

[0078] Table 4-2. Comparison of enzyme activities of three enzymes

[0079]

[0080] Figure 6 The electrophoresis pictures of human serum butyrylcholinesterase, recombinant butyrylcholinesterase produced by rabbit milk and recombinant butyrylcholinesterase-Fc fusion protein produced by CHO cells are shown by non-denaturing gel electrophoresis. Among them, 1 shows human serum butyrylcholinesterase; 2 shows recombinant butyrylcholinesterase produced by rabbit milk; 3 shows recombinant butyrylcholinesterase-Fc fusion protein produced by CHO cells. The results show that the electrophoresis position of recombinant butyrylcholinesterase-Fc fusion protein is roughly the same as that of human serum butyrylcholinesterase.

[0081] The human serum butyrylcholinesterase freeze-dried preparation was reconstituted with water for injection (5 mg / ml). The injection volume was: body weight (g) × 5ul. The mice were injected into the tail vein (≈20 g, n = 2, half male and half female); the injection volume was: body weight (g) × 5ul. The mice were injected into the peritoneum (≈20 g, n = 2, half male and half female). Blood was collected from the tail vein at different time points to detect enzyme activity. Samples: Blood was collected from the tail vein, placed in a heparin-treated PE tube, placed at room temperature for 30 minutes or at 4°C overnight, and the supernatant was centrifuged to detect enzyme activity.

[0082] The lyophilized preparation of recombinant butyrylcholinesterase produced in rabbit milk was reconstituted with water for injection (5 mg / ml). The injection volume was: body weight (g) × 10ul. The mice were injected into the tail vein (≈20 g, n = 10, half male and half female); the injection volume was: body weight (g) × 5ul. The mice were injected into the peritoneum (≈20 g, n = 8, half male and half female). Blood was collected from the tail vein at different time points to detect enzyme activity. Sample: Blood was collected from the tail vein, placed in a heparin-treated PE tube, placed at room temperature for 30 minutes or at 4°C overnight, and the supernatant was centrifuged to detect enzyme activity.

[0083] Recombinant butyrylcholinesterase-Fc fusion protein (1.3mg / ml) injection volume: body weight (g) × 19.23ul tail vein injection mice (≈20g, n = 3, 2 females and 1 male); injection volume: body weight (g) × 19.23ul intraperitoneal injection mice (≈20g, n = 6, half male and half female). Blood was collected from the tail vein at different time points to detect enzyme activity. Sample: Blood was collected from the tail vein, placed in a heparin-treated PE tube, placed at room temperature for 30 minutes or at 4°C overnight, and the supernatant was centrifuged to detect enzyme activity.

[0084] Refer to Table 4-3 and Figure 7 The experimental results show that the pharmacokinetic parameters of the recombinant butyrylcholinesterase-Fc fusion protein produced by CHO cells are basically the same as those of human serum butyrylcholinesterase, but its half-life is 1.3 times that of human serum butyrylcholinesterase (33.57 hours: 25.68 hours) and 35 times that of the recombinant butyrylcholinesterase produced by rabbit milk (33.57 hours: 0.96 hours). Combined with the enzymatic kinetic parameters and enzyme activity data of the previous embodiment, it is shown that the recombinant butyrylcholinesterase-Fc fusion protein greatly overcomes the defect of the short half-life of the recombinant butyrylcholinesterase produced by rabbit milk in vivo, without losing enzyme activity, and can be rapidly mass-produced in CHO cells. It is a successful enzymatic molecular modification design, and its half-life in the human body is expected to reach more than 12 days.

[0085] Table 4-3. Comparison of pharmacokinetic parameters of three enzymes in mice

[0086]

[0087] Example 5 Growth inhibition experiment of recombinant butyrylcholinesterase-Fc fusion protein produced by CHO cells on liver cancer cell line Huh7 and colon cancer cell line SW48

[0088] The liver cancer cell line Huh7 cells (derived from the JCRB cell bank) and the colon cancer cell line SW48 cells (derived from the ECACC cell bank) were seeded in a 96-well culture plate at 3000 cells per well and cultured overnight in Williams'Medium E (from Sigma-Aldrich) culture medium + 10% fetal bovine serum in a 5% CO2 incubator. On the second day, the recombinant butyrylcholinesterase-Fc fusion protein produced by the CHO cells purified in Example 4 was added to the wells at 0.5μm, 1.5μm and 2.5μm per well. After 72 hours of culture, 50ul Cell Titer Glo was added to each well of the culture plate to detect the proliferation of cells. The above experiment was repeated within one week. The specific experimental results are shown as follows. Figure 8 As shown in Figure 2, after treatment with 0.5 μM, 1.5 μM and 2.5 μM recombinant butyrylcholinesterase, the survival rates of the liver cancer cell line Huh7 were 77.9%, 59.3% and 43.4%, respectively. The half inhibitory concentration (IC 50 ) was 2.02 μm; the survival rates of colon cancer cell line SW48 were 87.4%, 79.7% and 73.1% respectively. The half inhibitory concentration (IC 50 The experimental results showed that the growth inhibition concentration data of recombinant butyrylcholinesterase-Fc fusion protein produced by CHO cells on liver cancer cell line Huh7 and colon cancer cell line SW48 were roughly the same as the growth inhibition concentration data of recombinant butyrylcholinesterase produced by rabbit milk on Huh7 and SW48.

[0089] Although the embodiments of the present invention are described in detail above, it is obvious to those skilled in the art that various modifications and variations can be made to these embodiments. However, it should be understood that such modifications and variations are within the scope and spirit of the present invention as described in the claims. Moreover, the present invention described herein may have other embodiments and may be implemented or realized in a variety of ways.

Claims

1. An application of a biological product, characterized in that: The biological product is used for preparing a drug for treating tumors. The biological product comprises at least one of a recombinant butyrylcholinesterase-albumin fusion protein and a recombinant butyrylcholinesterase-Fc fusion protein. The biological product adjusts the balance of acetylcholine and other related metabolic pathways by supplementing at least one of the exogenous recombinant butyrylcholinesterase-albumin fusion protein and the recombinant butyrylcholinesterase-Fc fusion protein to achieve the purpose of treating cancer. The tumor is liver cancer, non-small cell lung cancer, gastric cancer and colorectal cancer. The amino acid sequence of the recombinant butyrylcholinesterase-albumin fusion protein is shown in SEQ ID NO: 1 or SEQ ID NO: 2; the amino acid sequence of the recombinant butyrylcholinesterase-Fc fusion protein is shown in SEQ ID NO: 3 or SEQ ID NO:

4.

2. The use of the biological product according to claim 1, characterized in that: The recombinant butyrylcholinesterase-albumin fusion protein and the recombinant butyrylcholinesterase-Fc fusion protein are both derived from any one of an animal expression system, a viral transduction system, a plant expression system, a bacterial expression system, a CRISPR-Cas gene editing expression system and a yeast expression system.

3. The use of the biological product according to claim 2, characterized in that: The animal expression system is selected from any one of an insect expression system and a mammalian expression system.

4. The use of the biological product according to claim 3, characterized in that: The insect expression system includes the SF9 cell line.

5. The use of the biological product according to claim 3, characterized in that: The mammalian expression system includes the following mammalian cell expression systems: CHO, BHK, cow mammary epithelial cell MAC-T cell line, cow mammary epithelial cell BME-UV1 cell line, and HEK293.

6. The use of the biological product according to claim 2, characterized in that: The animal expression system includes any one or more of mice, rats and rabbits.

7. The use of the biological product according to claim 2, characterized in that: The N-terminus or C-terminus of the recombinant butyrylcholinesterase-albumin fusion protein and the recombinant butyrylcholinesterase-Fc fusion protein also includes a tag sequence for facilitating protein purification.

Citation Information

Patent Citations

  • Multivalent heteromultimer scaffold design and constructs

    CN103732628A

  • Method for producing recombinant human butyrylcholine esterase on large scale by utilizing biological platform of mammary gland of transgenic animal

    CN103898101A

  • Method for producing recombinant human BChE (butyrylcholinesterase) from transgenic animals by using gene knock-in and nuclear transfer technologies

    CN103966245A

  • Method for producing monoclonal antibodies by using transgenic animal mammary gland bioreactor

    CN104862318A

  • Application of acetylcholin esterase, butyrylcholine esterase or mutants thereof to preparation or screening of drug for tumor treatment

    CN107029218A